Posted by Michael Wonder on 19 Sep 2024
Daiichi Sankyo’s Vanflyta recommended by NICE for acute myeloid leukaemia
19 September 2024 - Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by NICE for certain cases of acute myeloid leukaemia.
The drug has been specifically recommended for routine NHS commissioning in England and Wales as an induction, consolidation and maintenance therapy for newly diagnosed FLT3-ITD-positive disease.
